血管修复治疗和生物可吸收血管支架。
Vascular restoration therapy and bioresorbable vascular scaffold.
机构信息
National Engineering Research Center For Biomaterials, Sichuan University, Chengdu 610064, China.
出版信息
Regen Biomater. 2014 Nov;1(1):49-55. doi: 10.1093/rb/rbu005. Epub 2014 Oct 20.
Abstract
This article describes the evolution of minimally invasive intervention technologies for vascular restoration therapy from early-stage balloon angioplasty in 1970s, metallic bare metal stent and metallic drug-eluting stent technologies in 1990s and 2000s, to bioresorbable vascular scaffold (BVS) technology in large-scale development in recent years. The history, the current stage, the challenges and the future of BVS development are discussed in detail as the best available approach for vascular restoration therapy. The criteria of materials selection, design and processing principles of BVS, and the corresponding clinical trial results are also summarized in this article.
摘要
本文描述了血管修复治疗的微创介入技术从 20 世纪 70 年代的早期球囊血管成形术，到 90 年代和 21 世纪的金属裸支架和药物洗脱支架技术，再到近年来大规模发展的生物可吸收血管支架（BVS）技术的演变历程。作为血管修复治疗的最佳方法，本文详细讨论了 BVS 的历史、现状、挑战和未来。本文还总结了 BVS 的材料选择标准、设计和加工原理以及相应的临床试验结果。
相似文献
1
Vascular restoration therapy and bioresorbable vascular scaffold.
Regen Biomater. 2014 Nov;1(1):49-55. doi: 10.1093/rb/rbu005. Epub 2014 Oct 20.
2
Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
Catheter Cardiovasc Interv. 2011 Jul 1;78(1):3-12. doi: 10.1002/ccd.22864. Epub 2011 Mar 16.
3
Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):189-197. doi: 10.1016/j.jcin.2014.10.005.
4
The Current Literature on Bioabsorbable Stents: a Review.
Curr Atheroscler Rep. 2019 Nov 25;21(12):54. doi: 10.1007/s11883-019-0816-4.
5
Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
JACC Cardiovasc Interv. 2013 Mar;6(3):247-57. doi: 10.1016/j.jcin.2012.10.013.
6
Patient profile and periprocedural outcomes of bioresorbable vascular scaffold implantation in comparison with drug-eluting and bare-metal stent implantation. Experience from ORPKI Polish National Registry 2014-2015.
Postepy Kardiol Interwencyjnej. 2016;12(4):321-328. doi: 10.5114/aic.2016.63632. Epub 2016 Nov 17.
7
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
Lancet. 2015 Jan 3;385(9962):43-54. doi: 10.1016/S0140-6736(14)61455-0. Epub 2014 Sep 14.
8
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016.
9
Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study).
Catheter Cardiovasc Interv. 2018 Oct 1;92(4):668-677. doi: 10.1002/ccd.27473. Epub 2018 Jan 22.
10
Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
Int J Cardiol. 2017 Sep 15;243:121-125. doi: 10.1016/j.ijcard.2017.05.053. Epub 2017 May 12.
引用本文的文献
1
A novel paclitaxel eluting bioresorbable vascular stent with a super flexible stent structure and round cross section struts fabricated using 3D printing technology with a rotating platform.
Regen Biomater. 2025 Jul 9;12:rbaf073. doi: 10.1093/rb/rbaf073. eCollection 2025.
2
Development of 4D-Printed Arterial Stents Utilizing Bioinspired Architected Auxetic Materials.
Biomimetics (Basel). 2025 Jan 26;10(2):78. doi: 10.3390/biomimetics10020078.
3
A comprehensive study on venous endovascular management and stenting in deep veins occlusion and stenosis: A review study.
Surg Open Sci. 2024 Apr 16;19:131-140. doi: 10.1016/j.sopen.2024.04.001. eCollection 2024 Jun.
4
A drug-free cardiovascular stent functionalized with tailored collagen supports in-situ healing of vascular tissues.
Nat Commun. 2024 Jan 25;15(1):735. doi: 10.1038/s41467-024-44902-2.
5
Advances in Fabrication Technologies for the Development of Next-Generation Cardiovascular Stents.
J Funct Biomater. 2023 Nov 10;14(11):544. doi: 10.3390/jfb14110544.
6
An extracellular matrix-mimetic coating with dual bionics for cardiovascular stents.
Regen Biomater. 2023 May 30;10:rbad055. doi: 10.1093/rb/rbad055. eCollection 2023.
7
PLLA Composites Combined with Delivery System of Bioactive Agents for Anti-Inflammation and Re-Endothelialization.
Pharmaceutics. 2022 Nov 30;14(12):2661. doi: 10.3390/pharmaceutics14122661.
8
Strategies for Enhancing Polyester-Based Materials for Bone Fixation Applications.
Molecules. 2021 Feb 13;26(4):992. doi: 10.3390/molecules26040992.
9
immunomodulation of magnesium on monocytic cell toward anti-inflammatory macrophages.
Regen Biomater. 2020 Aug;7(4):391-401. doi: 10.1093/rb/rbaa010. Epub 2020 Apr 14.
10
Automated Segmentation of Bioresorbable Vascular Scaffold Struts in Intracoronary Optical Coherence Tomography Images.
Int Conf Bioinform Biomed Eng. 2017 Oct;2017:297-302. doi: 10.1109/BIBE.2017.00-38. Epub 2018 Jan 11.
本文引用的文献
1
Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries.
JACC Cardiovasc Interv. 2014 Jun;7(6):688-95. doi: 10.1016/j.jcin.2013.11.024. Epub 2014 May 14.
2
Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives.
Cardiovasc Revasc Med. 2014 Mar;15(2):109-16. doi: 10.1016/j.carrev.2014.01.011. Epub 2014 Jan 30.
3
Evolution of implantable and insertable drug delivery systems.
J Control Release. 2014 May 10;181:1-10. doi: 10.1016/j.jconrel.2014.02.006. Epub 2014 Feb 15.
4
Bioresorbable scaffolds: rationale, current status, challenges, and future.
Eur Heart J. 2014 Mar;35(12):765-76. doi: 10.1093/eurheartj/eht542. Epub 2013 Dec 23.
5
Short-term safety and efficacy of the biodegradable iron stent in mini-swine coronary arteries.
Chin Med J (Engl). 2013;126(24):4752-7.
6
Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.
EuroIntervention. 2013 Jul;9(3):308-15. doi: 10.4244/EIJV9I3A52.
7
A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
EuroIntervention. 2013 May 20;9(1):75-83. doi: 10.4244/EIJV9I1A12.
8
Process of prototyping coronary stents from biodegradable Fe-Mn alloys.
Acta Biomater. 2013 Nov;9(10):8585-92. doi: 10.1016/j.actbio.2013.04.027. Epub 2013 May 7.
9
Gene expression profile of mouse fibroblasts exposed to a biodegradable iron alloy for stents.
Acta Biomater. 2013 Nov;9(10):8746-53. doi: 10.1016/j.actbio.2013.02.033. Epub 2013 Mar 14.
10
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
Lancet. 2013 Feb 23;381(9867):661-9. doi: 10.1016/S0140-6736(12)61962-X. Epub 2013 Jan 30.
Zotero 插件